Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
ES Antonarakis, AJ Armstrong, SM Dehm… - … cancer and prostatic …, 2016 - nature.com
… into AR-V expression in prostate cancers and their implications in contemporary prostate
cancer clinical care, as well as current efforts in therapeutic targeting of AR-Vs aiming to …
cancer clinical care, as well as current efforts in therapeutic targeting of AR-Vs aiming to …
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation
… targeting therapies but may retain sensitivity to chemotherapy. Here, we discuss the clinical
implications … whether such variants are passengers or drivers of aggressive clinical behavior. …
implications … whether such variants are passengers or drivers of aggressive clinical behavior. …
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
C Lu, LC Brown, ES Antonarakis… - … cancer and prostatic …, 2020 - nature.com
… and therapeutic targets in prostate cancer. Laboratory investigations reveal both challenges
… opportunities in targeting AR-Vs to overcome resistance to current AR-directed therapies. …
… opportunities in targeting AR-Vs to overcome resistance to current AR-directed therapies. …
Androgen receptor splice variant 7 in castration‐resistant prostate cancer: Clinical considerations
AH Bryce, ES Antonarakis - International Journal of Urology, 2016 - Wiley Online Library
… to overcome AR splice variant-driven disease. Galeterone (formerly TOK-001) is one potential
AR-V7-targeting drug that is the most advanced in its clinical development. In addition to …
AR-V7-targeting drug that is the most advanced in its clinical development. In addition to …
Regulation of androgen receptor variants in prostate cancer
… Given the important clinical implication of AR-Vs, this short … Therapeutic targeting of the AR
axis may result in active transcription … with AR-V-specific activities, in AR variant-driven CRPC. …
axis may result in active transcription … with AR-V-specific activities, in AR variant-driven CRPC. …
Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting
… of AR-Vs as therapeutic targets in CRPC. … clinical trials for Astellas, Pfizer, Janssen, Sanofi,
ESSA, and Arno that have an interest in targeting the androgen receptor in prostate cancer; …
ESSA, and Arno that have an interest in targeting the androgen receptor in prostate cancer; …
Molecular origin, expression regulation, and biological function of androgen receptor splicing variant 7 in prostate cancer
Y Chen, T Lan - Urologia Internationalis, 2021 - karger.com
… cancer drivers, and consequences of therapeutic pressures. With regard to the fundamental
importance of the androgen receptor (AR… role in castration-resistant prostate cancer (CRPC). …
importance of the androgen receptor (AR… role in castration-resistant prostate cancer (CRPC). …
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors
… The central question regarding the clinical significance of AR-V7 splice variant expression
in CRPC is whether it is simply a marker of enhanced AR transcription characteristic of …
in CRPC is whether it is simply a marker of enhanced AR transcription characteristic of …
Targeting the androgen receptor and overcoming resistance in prostate cancer
… cause of cancer death among men. Although therapies targeting the androgen receptor (AR) …
is universal and remains a major therapeutic challenge. Nonetheless, signaling via AR is …
is universal and remains a major therapeutic challenge. Nonetheless, signaling via AR is …
AR Structural Variants and Prostate Cancer
L Cato, M Shomali - Nuclear Receptors in Human Health and Disease, 2022 - Springer
… on inhibiting the androgen receptor (AR) through targeting of its C-… to androgen deprivation
and anti-androgen therapies, … unlikely that this variant is of major clinical significance in PCa. …
and anti-androgen therapies, … unlikely that this variant is of major clinical significance in PCa. …